The global artificial insemination market size was valued at USD 2.3 Billion in 2024, and it is expected to reach USD 4.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.15% from 2025 to 2033.
To get more information on this market, Request Sample
Infertility rates have increased significantly. For example, according to the World Health Organization (WHO) infertility affects approximately 17.5% of the adult population, or roughly one in every six people worldwide. Also, as per another article published by Sigle Care, one out of every four couples in developing nations has infertility. Rising infertility rates among men and women, caused by factors, such as lifestyle changes, increased stress, pollution, obesity, and delayed family planning, have increased demand for fertility treatments, such as artificial insemination. These reasons are projected to increase the artificial insemination market share in the approaching years.
Moreover, the use of artificial insemination in the animal breeding industry, especially in livestock and dairy production, is a significant market driver. According to an article published by the Food and Agriculture Organization, based on total cattle and buffalo populations, approximately 30% are artificially inseminated in Europe, North America, Australia, New Zealand, and Japan, with the rest of the world accounting for around 4%. AI in animals improves genetic quality, productivity, and efficiency in breeding operations, hence contributing to the overall growth of the AI business. These factors have a beneficial influence on the artificial insemination market prediction. Besides this, the surging availability of specialized fertility clinics equipped with advanced technologies and trained professionals is propelling the industry growth. More fertility clinics offering services like artificial insemination are opening, particularly in urban areas and developed regions, making these treatments more accessible. For example, in April 2023, Marubeni Corporation and TOWAKO REPRO BIO CELL INC., which operates an IVF facility in the Republic of the Philippines, formed a joint venture in the country's IVF market by investing in Conceive IVF Manila Inc., which operates an IVF diagnostic center. For the project, CIMI will collaborate with Kato Ladies Clinic. This project will improve CIMI's functions and transition it from an IVF diagnostic center to a full IVF clinic, providing comprehensive IVF-related services, escalating the artificial insemination market revenue.
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America dominates the market, owing to the expanding fertility services.
North America dominates the overall market. The rising infertility rates among men and women, caused by lifestyle changes, stress, pollution, delayed childbirth, and certain medical disorders, are a primary driving force in the market. Infertility rates in the region have continuously climbed, prompting many couples and individuals to seek treatment through artificial insemination. Furthermore, in North America, many women choose to postpone parenting for professional, financial, or emotional reasons. According to a Forbes article, as more women from all social classes have prioritized education and careers, delaying parenthood has become almost universal among American women. As maternal age increases, fertility decreases, prompting more people to seek assisted reproductive technologies (ART), such as artificial insemination, to conceive.
An increasing number of couples in Europe are facing infertility issues, leading to a higher demand for assisted reproductive technologies like artificial insemination. For instance, approximately 25 million people in Europe suffered from infertility in 2021.
The region has seen an increase in infertility cases due to factors, such as lifestyle changes, environmental pollution, and delayed childbearing. For instance, in India, about 27.5 million couples are trying to conceive, with about 10-15% facing fertility problems at some stage.
The region has witnessed a rise in infertility cases due to factors, such as lifestyle changes, environmental pollution, and delayed childbearing. For instance, in Brazil, it is estimated that 15-20% of couples of reproductive ages have some form of infertility issues. This has led to a higher demand for assisted reproductive technologies like artificial insemination.
The establishment of specialized fertility clinics equipped with advanced technologies has made these services more accessible. The clinics offer comprehensive reproductive services, attracting individuals seeking fertility treatments. For instance, in June 2024, the UAE's Minister of Tolerance and Coexistence launched the ART Fertility Clinic in Al Ain. This world-class clinic sets the standard for IVF services and will be a gift to the people of Al Ain. It is also a testament to ART Fertility's dedication to the UAE, both in terms of delivering the latest technology and attracting world-renowned medical personnel in the field of reproductive medicine.
Some of the leading artificial insemination market companies include Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women’s Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC, and Vitrolife AB, among many others. For instance, in September 2024, FUJIFILM Irvine Scientific, Inc., a global inventor and manufacturer of cell culture solutions for the Life Sciences, expanded its product portfolio and services by aligning some commercial operations with its sister company, FUJIFILM Wako Chemicals U.S.A., Corp.
Report Features | Details |
---|---|
Market Size in 2024 | USD 2.3 Billion |
Market Forecast in 2033 | USD 4.6 Billion |
Market Growth Rate 2025-2033 | 7.15% |
Units | Billion USD |
Scope of the Report | Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Types Covered | Intrauterine, Intracervical, Intravaginal, Intratubal |
Source Types Covered | AIH-Husband, AID-Donor |
End Uses Covered | Hospitals and Clinics, Fertility Centers, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women’s Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC, Vitrolife AB, etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |